Joseph Samuel Dolina

Joseph Samuel Dolina

Auto-generated profile, based on publicly available information

Joseph Samuel Dolina

Division of Developmental Immunology, La Jolla Institute for Immunology, La Jolla, California, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JDJoseph S. Dolina
Joseph S. Dolina
JLJoey Lee
Joey Lee
SBSpencer E. Brightman
Spencer E. Brightman
SMSara McArdle
Sara McArdle
SHSamantha M. Hall
Samantha M. Hall
SSStephen P. Schoenberger
Stephen P. Schoenberger
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells. We explored whether the response to ICB of an aggressive low-TMB squamous cell tumor could be improved through combination immunotherapy using functionally defined NeoAg as targets for endogenous CD4+ and CD8+ T cells. We found that, whereas vaccination with CD4+ or CD8+ NeoAg alone did not offer prophylactic or therapeutic immunity, vaccines containing NeoAg recognized by both subsets overcame ICB resistance and led to the eradication of large established tumors that contained a subset of PD-L1+ tumor-initiating cancer stem cells (tCSC), provided the relevant epitopes were physically linked. Therapeutic CD4+/CD8+ T cell NeoAg vaccination produced a modified tumor microenvironment (TME) with increased numbers of NeoAg-specific CD8+ T cells existing in progenitor and intermediate exhausted states enabled by combination ICB-mediated intermolecular epitope spreading. We believe that the concepts explored herein should be exploited for the development of more potent personalized cancer vaccines that can expand the range of tumors treatable with ICB.

13 December 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NBNatalija Van Braeckel-Budimir
Natalija Van Braeckel-Budimir
JDJoseph Samuel Dolina
Joseph Samuel Dolina
JWJie Wei
Jie Wei
XWXiao Wang
Xiao Wang
SCShih-Hsun Chen
Shih-Hsun Chen
SSShahram Salek-Ardakani
Shahram Salek-Ardakani
Background: Programmed death (ligand) 1 (PD-(L)1) blockade and OX40/4-1BB costimulation have been separately evaluated in the clinic to elicit potent antitumor T cell responses. The precise mechanisms underlying single agent activity are incompletely understood. It also remains unclear if combining individual therapies leads to synergism, elicits novel immune mechanisms, or invokes additive effects. Methods: We performed high-dimensional flow cytometry and single-cell RNA sequencing-based immunoprofiling of murine tumor-infiltrating lymphocytes (TILs) isolated from hosts bearing B16 or MC38 syngeneic tumors. This baseline infiltrate was compared to TILs after treatment with either anti-PD-(L)1, anti-OX40, or anti-4-1BB as single agents or as double and triple combinatorial therapies. Fingolimod treatment and CXCR3 blockade were used to evaluate the contribution of intratumoral versus peripheral CD8+ T cells to therapeutic efficacy. Results: We identified CD8+ T cell subtypes with distinct functional and migratory signatures highly predictive of tumor rejection upon treatment with single agent versus combination therapies. Rather than reinvigorating terminally exhausted CD8+ T cells, OX40/4-1BB agonism expanded a stem-like PD-1loKLRG-1+Ki-67+CD8+ T cell subpopulation, which PD-(L)1 blockade alone did not. However, PD-(L)1 blockade synergized with OX40/4-1BB costimulation by dramatically enhancing stem-like TIL presence via a CXCR3-dependent mechanism. Conclusions: Our findings provide new mechanistic insights into the interplay between components of combinatorial immunotherapy, where agonism of select costimulatory pathways seeds a pool of stem-like CD8+ T cells more responsive to immune checkpoint blockade (ICB).

3 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JDJoseph S. Dolina
Joseph S. Dolina
JLJoey Lee
Joey Lee
EMEugene L. Moore
Eugene L. Moore
JHJennifer L. Hope
Jennifer L. Hope
DGDonald T. Gracias
Donald T. Gracias
SSStephen P. Schoenberger
Stephen P. Schoenberger
Significance: The CD4+Tregresponse following acuteListeriainfection is heterogeneous and deploys two distinct modes of suppression coinciding with initial pathogen exposure and resolution of infection. This bimodal suppression of CD8+T cells during priming and contraction is mediated by separate Treglineages. These findings make a significant contribution to our understanding of the functional plasticity inherent within Tregs, which allows these cells to serve as a sensitive and dynamic cellular rheostat for the immune system to prevent autoimmune pathology in the face of inflammation attendant to acute infection, enable expansion of the pathogen-specific response needed to control the infection, and reestablish immune homeostasis after the threat has been contained.

7 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JDJoseph S. Dolina
Joseph S. Dolina
JLJoey Lee
Joey Lee
SBSpencer E. Brightman
Spencer E. Brightman
SMSara McArdle
Sara McArdle
SHSamantha M. Hall
Samantha M. Hall
SSStephen P. Schoenberger
Stephen P. Schoenberger
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells. We explored whether the response of an aggressive low TMB squamous cell tumor to ICB could be improved through combination immunotherapy using functionally defined NeoAg as targets for endogenous CD4 + and CD8 + T cells. We found that, whereas vaccination with CD4 + or CD8 + NeoAg alone did not offer prophylactic or therapeutic immunity, vaccines containing NeoAg recognized by both subsets overcame ICB resistance and led to the eradication of large established tumors that contained a subset of PD-L1 + tumor-initiating cancer stem cells (tCSC), provided the relevant epitopes were physically linked. Therapeutic CD4 + /CD8 + T cell NeoAg vaccination produced a modified tumor microenvironment (TME) with increased numbers of NeoAg-specific CD8 + T cells existing in progenitor and intermediate exhausted states enabled by combination ICB-mediated intermolecular epitope spreading. The concepts explored herein should be exploited for the development of more potent personalized cancer vaccines that can expand the range of tumors treatable with ICB.